Published in N Engl J Med on March 30, 2000
Risk of endometrial cancer in relation to medical conditions and medication use. Cancer Epidemiol Biomarkers Prev (2009) 1.23
Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol (2005) 0.98
Current Treatment Options for the Metabolic Syndrome. Curr Treat Options Cardiovasc Med (2005) 0.90
Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol. Am J Hypertens (2011) 0.86
Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome. J Am Soc Hypertens (2008) 0.85
Management of diabetic hypertensives. Indian J Endocrinol Metab (2011) 0.82
Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination. Vasc Health Risk Manag (2007) 0.80
Walking and running produce similar reductions in cause-specific disease mortality in hypertensives. Hypertension (2013) 0.80
Effects of olmesartan on blood pressure and insulin resistance in hypertensive patients with sleep-disordered breathing. Heart Vessels (2011) 0.78
Effect of intensive multifactorial treatment on the intima-media thickness of large arteries in patients with new-onset type 2 diabetes mellitus. J Zhejiang Univ Sci B (2012) 0.75
Reduced total and cause-specific mortality from walking and running in diabetes. Med Sci Sports Exerc (2014) 0.75
Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med (2000) 0.75
Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation (1999) 8.04
Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int (2006) 7.02
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA (2001) 4.75
Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA (1996) 4.03
Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis (2000) 3.37
Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant (1997) 2.13
A perspective on converting enzyme inhibitors and calcium channel antagonists in diabetic renal disease. Arch Intern Med (1991) 2.02
Diabetes mellitus and hypertension. Hypertension (1992) 1.93
Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab (2001) 1.93
Altered platelet calcium metabolism as an early predictor of increased peripheral vascular resistance and preeclampsia in urban black women. N Engl J Med (1990) 1.80
Diabetes mellitus: a disease of abnormal cellular calcium metabolism? Am J Med (1994) 1.74
Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy. Ann Intern Med (1993) 1.65
Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol (1999) 1.61
Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab (2002) 1.47
Plasma norepinephrine responses to posture and isometric exercise increase with age in the absence of obesity. J Gerontol (1983) 1.46
Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol (1996) 1.41
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int (2006) 1.37
A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med (1990) 1.35
Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. J Hum Hypertens (2007) 1.29
Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med (2000) 1.26
Metoclopramide stimulates prolactin secretion in man. J Clin Endocrinol Metab (1976) 1.18
17 beta-Estradiol attenuates voltage-dependent Ca2+ currents in A7r5 vascular smooth muscle cell line. Am J Physiol (1994) 1.16
Development of explicit criteria to measure adherence to hypertension guidelines. J Hum Hypertens (2006) 1.15
Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab (2010) 1.13
Reduced contractile response to insulin and IGF-I in ventricular myocytes from genetically obese Zucker rats. Am J Physiol Heart Circ Physiol (2000) 1.10
Role of the sympathetic nervous system in blood pressure maintenance in obesity. J Clin Endocrinol Metab (1982) 1.09
Cost effectiveness of 24-hour ambulatory blood pressure monitoring in evaluation and treatment of essential hypertension. Am J Hypertens (1994) 1.06
Downregulation of K(+) channel genes expression in type I diabetic cardiomyopathy. Biochem Biophys Res Commun (2001) 1.04
Enhanced 24-hour norepinephrine and renin secretion in young patients with essential hypertension: relation with the circadian pattern of arterial blood pressure. Am J Cardiol (1985) 1.03
Acute airway obstruction due to a benign cervical goiter. Otolaryngol Head Neck Surg (1987) 1.02
Diabetes mellitus and diabetes-associated vascular disease. Trends Endocrinol Metab (2001) 1.00
Ambulatory blood pressure monitoring in a nonacademic setting. Effects of age and sex. Am J Hypertens (1992) 0.99
Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension (1994) 0.99
Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM (2006) 0.98
Clinical review 91: Female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab (1997) 0.98
Altered inotropic response to IGF-I in diabetic rat heart: influence of intracellular Ca2+ and NO. Am J Physiol (1998) 0.97
Impairment of cardiopulmonary baroreflex after cardiac transplantation in humans. Circulation (1987) 0.97
Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med (1987) 0.95
Salt sensitivity and systemic hypertension in the elderly. Am J Cardiol (1988) 0.95
Insulin attenuates vasopressin-induced calcium transients and a voltage-dependent calcium response in rat vascular smooth muscle cells. J Clin Invest (1991) 0.95
Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int (1999) 0.95
Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia. Am J Med (1991) 0.95
Hyperpigmentation, vitiligo, and Addison's disease. Cutis (1985) 0.93
Metabolism of exogenous human chorionic gonadotrophin in men. J Endocrinol (1979) 0.93
Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int (1993) 0.93
Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med (1993) 0.93
Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance? J Hum Hypertens (2006) 0.92
Acute interstitial nephritis with glomerulopathy due to nonsteroidal anti-inflammatory agents: a review of its clinical spectrum and effects of steroid therapy. J Clin Pharmacol (1990) 0.92
Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model. Hypertension (2001) 0.91
Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens (2013) 0.91
Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. Diabetes Obes Metab (2008) 0.90
Leydig cell tumor induced hypercalcemia in the Fischer rat: morphometric and histochemical evidence for a humoral factor that activates osteoclasts. Am J Pathol (1982) 0.90
Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats. J Pharmacol Exp Ther (1996) 0.89
Hypertension symposium: newer topics on normal and abnormal blood pressure regulatory mechanisms. West J Med (1983) 0.89
Dopaminergic mediation of the natriuretic response to volume expansion. J Lab Clin Med (1985) 0.89
Pulmonary scar carcinoma. A clinicopathologic analysis. Cancer (1983) 0.89
Cardiovascular disease in the diabetic woman. J Clin Endocrinol Metab (1999) 0.89
Relative androgenicity, blood pressure levels, and cardiovascular risk factors in young healthy women. Am J Hypertens (1995) 0.88
Pathophysiology of male hypogonadism associated with endogenous hyperestrogenism. Evidence for dual defects in the gonadal axis. N Engl J Med (1985) 0.88
Blood pressure and hormone changes associated with weight reduction in the obese. Hypertension (1982) 0.88
Circadian variation in plasma dopamine levels in man. J Endocrinol Invest (1984) 0.88
Influence of age on contractile response to insulin-like growth factor 1 in ventricular myocytes from spontaneously hypertensive rats. Hypertension (1999) 0.88
Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production. Diabetes (1997) 0.88
Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle. Endocrinology (1996) 0.87
Adrenal function following coronary bypass surgery. Am Heart J (1985) 0.87
Therapeutic approaches to achieve desired blood pressure goals: focus on calcium channel blockers. Cardiovasc Drugs Ther (2000) 0.87
Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells. Endocrinology (1998) 0.87
Inhibition of Rho protein stimulates iNOS expression in rat vascular smooth muscle cells. Am J Physiol Heart Circ Physiol (2000) 0.86
Gender differences in vascular compliance in young, healthy subjects assessed by pulse contour analysis. J Clin Hypertens (Greenwich) (2001) 0.86
Dopaminergic modulation of aldosterone secretion in man is unaffected by glucocorticoids and angiotensin blockade. J Clin Endocrinol Metab (1981) 0.86
Metformin but not glyburide prevents high glucose-induced abnormalities in relaxation and intracellular Ca2+ transients in adult rat ventricular myocytes. Diabetes (1999) 0.86
Calcium and protein kinase C mediate high-glucose-induced inhibition of inducible nitric oxide synthase in vascular smooth muscle cells. Hypertension (1998) 0.85
Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology (1996) 0.85
Role of cellular calcium metabolism in abnormal glucose metabolism and diabetic hypertension. Am J Med (1989) 0.85
Effects of high calcium intake on blood pressure and calcium metabolism in young SHR. Hypertension (1984) 0.85
Altered dopaminergic modulation of sympathetic nervous system activity in idiopathic edema. J Endocrinol Invest (1984) 0.85
Comparison of metoclopramide with other dynamic tests of prolactin secretion. J Clin Endocrinol Metab (1976) 0.85
Reductions in plasma catecholamines and blood pressure during weight loss in obese subjects. Acta Endocrinol (Copenh) (1983) 0.85
A role for calcium in radiocontrast-induced reductions in renal hemodynamics. Kidney Int (1985) 0.84
Troglitazone attenuates high-glucose-induced abnormalities in relaxation and intracellular calcium in rat ventricular myocytes. Diabetes (1996) 0.84
Reductions in total and extracellular water associated with calcium-induced natriuresis and the antihypertensive effect of calcium in blacks. Am J Hypertens (1988) 0.84
Vascular insulin abnormalities, hypertension, and accelerated atherosclerosis. Am J Kidney Dis (1993) 0.84
Dissociation of 24-hour catecholamine levels from blood pressure in older men. Hypertension (1986) 0.84
Hypertension in the elderly. Am J Med (1987) 0.84
Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med (1990) 0.84
An update on perioperative management of diabetes. Arch Intern Med (1999) 0.84
Dopaminergic control of prolactin and blood pressure: altered control in essential hypertension. Hypertension (1982) 0.83
Dopaminergic control of plasma catecholamine and aldosterone responses to acute stimuli in normal man. J Clin Endocrinol Metab (1980) 0.83
Growth hormone and prolactin secretion in Huntington's disease. Life Sci (1979) 0.83
Dopaminergic modulation of renin release. Clin Exp Hypertens (1981) 0.83
The use of clonidine for management of opiate abstinence in a chronic pain patient. Mayo Clin Proc (1982) 0.83
Dopaminergic regulation of natriuretic response to acute volume expansion in dogs. Clin Sci (Lond) (1985) 0.83
Magnesium responsiveness to insulin and insulin-like growth factor I in erythrocytes from normotensive and hypertensive subjects. J Clin Endocrinol Metab (1998) 0.83
Regulation of Na+,K(+)-ATPase gene expression by insulin in vascular smooth muscle cells. Am J Hypertens (1993) 0.82
Relationship between urinary dopamine production and natriuresis after acute intravascular volume expansion with sodium chloride in dogs. Endocrinology (1984) 0.82
Effect of dexamethasone on prolactin and TSH responses to TRH and metoclopramide in man. J Clin Endocrinol Metab (1977) 0.82
Insulin like growth factor 1 increases vascular smooth muscle nitric oxide production. Life Sci (1997) 0.82
Impaired calcium metabolism associated with hypertension in Zucker obese rats. Metabolism (1990) 0.81
Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes. J Clin Pharmacol (1996) 0.81
Altered cation transport in non-insulin-dependent diabetic hypertension: effects of dietary calcium. J Hypertens Suppl (1988) 0.81